The Nonhuman Primate (NHP) Core seeks to consolidate the NHP experimental objectives of the Consortia for AIDS Vaccine Research (CAVR) in Nonhuman Primates proposal into a single Core composed of highly experienced research personnel. This Core will provide the expertise and technical support required to insure successful completion of the multifaceted and extensive NHP research protocols supporting Project 1 """"""""Adenovirus and Poxvirus Mediated Protection Against Mucosal SIV Infection"""""""", Project 2 - """"""""CMV Vectors and Early Control of Mucosal SIV Challenge"""""""", Project 3 - """"""""Live Attenuated SIV-Mediated Protection Against Mucosal SIV Infection"""""""", Project 4 - """"""""Mechanisms of Antibody Interception of Virus Following SHIV Challenge"""""""" and Project 5 - """"""""Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection"""""""". These projects constitute a collaborative, interactive, and comprehensive investigation of acute mucosal SIV infection and the systematic evaluation of vaccines and which immune responses can block or modulate these early events of SIV infection to prevent infection or disease. The global objective of the Core is to provide leadership and technical expertise to ensure consistency and quality control in animal selection, execution of study protocols, application of experimental animal procedures, animal observations and data collection necessary to meet the comprehensive investigation objectives of the CAVR.'s To accomplish this, the Core will manage and directly supervise all NHP studies for the CAVR including: 1) animal selection;2) animal housing and general husbandry;3) experimental procedures and clinical management;4) specimen collection and processing;5) necropsy studies;and 6) acquisition and management of animal demographic, physiologic, clinical, and pathologic data.
NHP research is expensive, and requires highly specialized resources and personnel. Consolidation of multiple interactive projects into a integrative multdicipline core had decided advantages in correlation of results, efficient animals handling and speciment process, use of fewer animals and efficient use of animals facility space and resources.
|Zeng, Ming; Smith, Anthony J; Shang, Liang et al. (2016) Mucosal Humoral Immune Response to SIVmac239âˆ†nef Vaccination and Vaginal Challenge. J Immunol 196:2809-18|
|Barouch, Dan H; Ghneim, Khader; Bosche, William J et al. (2016) Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys. Cell 165:656-67|
|Tartaglia, Lawrence J; Chang, Hui-Wen; Lee, Benjamin C et al. (2016) Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences. PLoS Pathog 12:e1005431|
|Martinez-Navio, JosÃ© M; Fuchs, Sebastian P; PedreÃ±o-LÃ³pez, SÃ²nia et al. (2016) Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol Ther 24:76-86|
|Larocca, Rafael A; Abbink, Peter; Peron, Jean Pierre S et al. (2016) Vaccine protection against Zika virus from Brazil. Nature 536:474-8|
|Stephenson, Kathryn E; Neubauer, George H; Bricault, Christine A et al. (2016) Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infect Dis 3:ofw100|
|Stephenson, Kathryn E; D'Couto, Helen T; Barouch, Dan H (2016) New concepts in HIV-1 vaccine development. Curr Opin Immunol 41:39-46|
|Billingsley, James M; Rajakumar, Premeela A; Connole, Michelle A et al. (2015) Characterization of CD8+ T cell differentiation following SIVÎ”nef vaccination by transcription factor expression profiling. PLoS Pathog 11:e1004740|
|Adnan, Sama; Colantonio, Arnaud D; Yu, Yi et al. (2015) CD8 T cell response maturation defined by anentropic specificity and repertoire depth correlates with SIVÎ”nef-induced protection. PLoS Pathog 11:e1004633|
|Barouch, Dan H; Alter, Galit; Broge, Thomas et al. (2015) Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349:320-4|
Showing the most recent 10 out of 45 publications